Cancer Control最新文献

{"title":"Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study.","authors":"Yi Peng, De Wu, Jing Tang, Xiaobing Li","doi":"10.1177/10732748251318383","DOIUrl":"10.1177/10732748251318383","url":null,"abstract":"<p><strong>Objective: </strong>To develop personalized treatment strategies for maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC).</p><p><strong>Materials and methods: </strong>We analyzed data from ES-SCLC patients who achieved stable disease (SD) following initial chemotherapy combined with immunotherapy. These patients subsequently received maintenance therapy (MT) with a combination of anlotinib and PD-1/L1 inhibitors. The primary endpoints included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (AEs).</p><p><strong>Results: </strong>Preliminary findings suggest that this regimen is highly effective, with a median PFS of 6 months and OS of 13.5 months, alongside a DCR exceeding 60%. Subgroup analysis revealed enhanced efficacy in patients with fewer than three metastatic sites and those who experienced hypertension, proteinuria, or hand-foot syndrome during MT. Mechanistic studies showed a notable increase in the proportion of CD8+ T cells in the peripheral blood post-MT, correlating with improved outcomes. These findings imply that the therapeutic effect of MT may be partly due to the direct activation of CD8+ T cells, producing a synergistic anti-tumor response. Despite the prevalence of AEs, AEs were generally manageable, underscoring anlotinib's potential in this context.</p><p><strong>Conclusion: </strong>The combination of anlotinib and PD-1/L1 inhibitors offers promising efficacy and manageable AEs in MT, making it a viable option for ES-SCLC patients who achieve SD post-initial therapy. These results justify further prospective studies to validate this approach.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251318383"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of GPX1 (rs1050450) Variants in Ovarian Cancer Susceptibility Within a Turkish Population.","authors":"Baker Alsheikh, Rukset Attar, Seda Güleç Yilmaz, Sara Yaser Barham, Selvi Duman Bakırezer","doi":"10.1177/10732748251332441","DOIUrl":"https://doi.org/10.1177/10732748251332441","url":null,"abstract":"<p><p>IntroductionOvarian cancer (OC) remains one of the most lethal gynecological malignancies, primarily due to challenges in early detection and the consequent poor prognosis. Genetic predisposition plays a critical role in OC development, with the Glutathione Peroxidase 1 (GPX1) gene receiving increasing attention. The GPX1 gene polymorphism rs1050450 has been implicated in various cancers, potentially through its impact on oxidative stress mechanisms.ObjectiveThis study aimed to investigate the association between the GPX1 (rs1050450) polymorphism and the risk of developing OC in a Turkish population.MethodsA retrospective case-control study was conducted involving 90 women diagnosed with OC and 90 healthy controls. Genotyping of the GPX1 (rs1050450) polymorphism was performed using real-time PCR (RT-PCR). Statistical analyses were conducted using the SPSS software, with chi-square and t-tests applied where appropriate.ResultsThe CC genotype of the GPX1 (rs1050450) polymorphism was significantly associated with a reduced risk of OC (<i>P</i> = 0.002; OR = 0.304; 95% CI = 0.161-0.577), whereas the TT genotype was linked to an increased risk, demonstrating a threefold elevation in susceptibility (<i>P</i> = 0.036; OR = 3.308; 95% CI = 1.024-10.682). Additionally, the T allele was associated with an approximately threefold increased risk of developing OC (<i>P</i> = 0.0002).ConclusionThese findings suggest that the GPX1 (rs1050450) polymorphism may play a significant role in OC susceptibility, with the CC genotype offering potential protective effects and the TT genotype indicating increased risk. This genetic variant may serve as a useful marker for assessing OC risk; however, further studies involving larger and more diverse populations are needed to validate these results.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251332441"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144051603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender Difference in the Trend and Forecast Analysis of Changes in the Burden of Disease of Pancreatic Cancer Attributable to Smoking in China, 1990-2021.","authors":"Haodi Wang, Wenhao Sun, Jiaqian Zuo, Gang Wang, Zhengming Deng, Zhiwei Jiang","doi":"10.1177/10732748251341521","DOIUrl":"https://doi.org/10.1177/10732748251341521","url":null,"abstract":"<p><p>BackgroundPancreatic cancer is one of the most aggressive malignant tumors worldwide, often resulting in poor prognosis. Smoking is widely recognized as a significant risk factor for this disease.MethodsThis study extracted data on the disease burden of pancreatic cancer attributable to smoking in China from the Global Burden of Disease 2021 (GBD 2021) database. A total of 447 334 individuals were included in the analysis. A joinpoint regression model was used to calculate the annual percentage change (APC) and average annual percentage change (AAPC) to assess trends in the disease burden from 1990 to 2021. The age-period-cohort model was applied to explain the epidemiological trends of the disease by controlling for variables associated with age, period, and birth cohort. Decomposition analysis was conducted to quantify the relative contributions of population growth, population aging, and epidemiological changes. The Autoregressive Integrated Moving Average (ARIMA) model was utilized to forecast the burden of pancreatic cancer due to smoking in China over the next 15 years.ResultsFrom 1990 to 2021, the age-standardized mortality rate (ASMR) and the age-standardized disability-adjusted life years rate (ASDR) due to smoking-related pancreatic cancer in China exhibited an upward trend. By 2021, the total number of deaths and disability-adjusted life years (DALYs) had almost doubled compared to 1990. The mortality and DALY rates increased with age, peaking at approximately 85 years and 70 years, respectively, indicating a substantial burden on the elderly population. Furthermore, we predict that female ASMR and ASDR may start to decline in the next 15 years; however, the absolute burden remains unchanged. Conversely, the ASMR and ASDR for males continue to rise, indicating an increasing burden, with the male burden consistently surpassing that of females.ConclusionsThis study demonstrates that from 1990 to 2021, the burden of pancreatic cancer attributable to smoking in China has intensified, with significant disparities related to sex and age. The future outlook appears quite severe, given the large population base and accelerating population aging. Strong smoking cessation and control measures specifically targeting elderly males are imperative to limit tobacco exposure among high-risk groups, as these measures are crucial for alleviating the burden of pancreatic cancer in China.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251341521"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12065983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Risk Factors for Cause-specific Mortality in Advanced Papillary Thyroid Cancer and Construction of a Competing Risk Model: A SEER-Based Study.","authors":"Yunyi Yang, Xiaoli He, Xiaoxiao Qu, Shufa Tan, Xinyi Fu, Jiawen You, Weijin Huang, Jiayuan Cai, Yanming He, Hongjie Yang","doi":"10.1177/10732748251336412","DOIUrl":"https://doi.org/10.1177/10732748251336412","url":null,"abstract":"<p><p>IntroductionPapillary thyroid carcinoma (PTC) generally has a favorable prognosis, yet advanced PTC has higher recurrence and mortality risks. This study constructs and validates a competing risk model for cause-specific mortality (CSM) in advanced PTC.MethodsStage III-IV PTC cases (AJCC 7th edition) from the SEER database (2010-2015) were analyzed. Patients were split into training and validation sets (7:3). Univariate and multivariate analyses identified independent CSM predictors, forming the basis of a risk prediction nomogram. Model accuracy was evaluated via the C-index and calibration curve.ResultsA total of 11 913 advanced PTC cases were analyzed. Competing risk model analysis unraveled that age, race, sex, grade, stage, T stage, M stage, surgery, chemotherapy, and tumor size were risk factors for CSM in advanced PTC. The AUC values of the constructed nomogram in predicting 3-, 5-, and 8-year survival were 0.931 (95%CI 0.909-0.953), 0.915 (95%CI 0.897-0.933), and 0.902 (95%CI 0.883-0.92) in the training set, and 0.948 (95%CI 0.916-0.981), 0.93 (95 % CI 0.903-0.957), and 0.917 (95%CI 0.891-0.943) in the validation cohort, respectively. The C-index of the nomogram for advanced PTC was 0.908 and 0.921 in the training and validation cohorts, respectively. The calibration curve unveiled that the predicted estimates by the model were basically congruent with the observed values, suggesting a high degree of calibration.ConclusionThe competing risk model offers a reliable tool for assessing prognosis in advanced PTC, supporting personalized treatment and risk management in clinical practice.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251336412"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12034963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatic Cancer in High-Income Asia-Pacific: A Population-Based Study.","authors":"Donghong Wang, Zhibin Ma","doi":"10.1177/10732748251330713","DOIUrl":"10.1177/10732748251330713","url":null,"abstract":"<p><p>BackgroundPancreatic cancer places a substantial global health and economic burden. However, the epidemiological characteristics and chronological trends of pancreatic cancer in high-income Asia-Pacific have not been systematically analyzed.MethodsData obtained from the GBD 2021 database were used for this cross-country secondary analysis. We used Joinpoint regression to analyze the temporal trends of pancreatic cancer disease burden in the high-income Asia-Pacific. Age-period-cohort model was used to estimate and describe the impact of age, period, and cohort effects on health outcomes. Bayesian age-period-cohort model was used for the projection of pancreatic cancer incidence from 2022 to 2036.ResultsIn high-income Asia-Pacific, the age-standardized prevalence rate (ASPR), mortality rate (ASMR), and disability-adjusted life-years (DALYs) rate (ASDR) were estimated to be 11.2 (95% UI, 9.69-12.17), 9.56 (95% UI, 8.34-10.34), and 197.6 (95% UI, 178.87-210.6) per 100 000 population, respectively, in 2021, which were all higher than those in across Asia. From 1990 to 2002, the age-standardized incidence rates (ASIRs) trend was rather stable. Instead, the ASIRs trend went up gradually from 2002 to 2011 in both males (APC = + 1.03, 95% CI: 0.85, 1.20) and females (APC = + 1.64, 95% CI: 1.40, 1.89). ASIRs and ASMRs went up considerably with increasing age, especially over 60. The ASIRs in the high-income Asia-Pacific region are predicted to go down in the years ahead, from approximately 12.81 in 2021 to approximately 11.11 in 2036 for males, and from approximately 8.97 in 2021 to approximately 8.42 in 2036 for females.ConclusionA comprehensive upward trend in ASIRs, ASPRs, ASMRs, and ASDRs of pancreatic cancer was observed in the high-income Asia-Pacific between 1990 and 2021. Given the poor prognosis of pancreatic cancer, prevention strategies are paramount, especially for modifiable factors like smoking, alcohol drinking, and obesity.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251330713"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11967221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143774626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing Artificial Intelligence-Powered Virtual Tumor Board Meetings in Pakistan.","authors":"Saqib Raza Khan, Anoud Khan, Aryan Tareen","doi":"10.1177/10732748251331753","DOIUrl":"10.1177/10732748251331753","url":null,"abstract":"<p><p>Equitable cancer care in low- and middle-income countries is crucial as mortality rates continue to rise. Artificial intelligence (AI)-powered Virtual Tumor Board Meetings (VTBMs) offer an innovative solution that facilitates real-time collaboration between experts to improve patient outcomes. By integrating AI-powered tools, VTBMs can improve diagnostic accuracy and personalize treatment plans using various data sources such as medical images and genomic profiles. In Pakistan, with limited healthcare resources and a high economic burden, the introduction of AI-powered VTBMs has the potential to revolutionize cancer care. This strategic approach will not only address the current challenges in Pakistan, but also serve as a model for improving cancer care in various developing countries.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251331753"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143732579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cultural and Linguistic Adaptation of an Evidence-Based Tailored Navigation Intervention to Increase Cancer Screening Uptake Among Southeast Asian Women.","authors":"Jennifer Kue, Judith A Tate, Bárbara Piñeiro, Laura A Szalacha, Bounthanh Phommasathit, Somany Pich, Usha Menon","doi":"10.1177/10732748251329867","DOIUrl":"10.1177/10732748251329867","url":null,"abstract":"<p><p>BackgroundSoutheast Asian immigrant women in the U.S. have high rates of breast and cervical cancer, yet they are the least likely of all racial/ethnic groups to get screened. To address this disparity, we adapted the evidence-based Tailored Intervention Messaging System^© (TIMS^©), which uses tailored messages and navigation by culturally and linguistically matched community health advisors to overcome barriers to cancer screening.ObjectivesThis study describes the cultural and linguistic adaptation of TIMS^© to improve breast and cervical cancer screening among Southeast Asian immigrant women in the U.S.MethodsGuided by Stirman et al.'s adaptation framework, we conducted focus groups and in-depth interviews to identify key constructs related to cancer screening (knowledge, perceived barriers, perceived risk, benefits, self-efficacy). Using the TIMS^© and the thematic content from qualitative data, we modified messages for content and context. Messages were divided into three categories: 1) existing messages identified in thematic analyses, 2) existing messages not identified in thematic analyses, and 3) new messages that emerged from thematic analyses.ResultsContextual and content modifications were made to the TIMS^© message library. Messages were translated into Lao, Khmer, and Vietnamese. Through an iterative process, the investigator, community health advisors, and cultural community advisory board members reviewed and revised the messages for translation accuracy, relevance, and clarity.ConclusionUsing relatable language and context is critical to engaging women from Southeast Asian communities in improving breast and cervical cancer screening uptake. This adaptation approach can be applied to tailor interventions for other languages, cultures, and underrepresented groups.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251329867"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Socioeconomic Status and Breast Cancer Treatment in the United States: Results From a Systematic Literature Review.","authors":"Sreelatha Akkala, Mohammed Zuber, Julie Alaere Atta, Nompumelelo O Mzizi, Jyothi Akkula","doi":"10.1177/10732748251341520","DOIUrl":"10.1177/10732748251341520","url":null,"abstract":"<p><p>BackgroundIn 2024, breast cancer is the second most common cancer globally, affecting 2.3 million women. In the United States (US), 310 720 new female breast cancer cases were estimated in 2024. Existing research has identified substantial disparities in breast cancer treatment and survival based on socioeconomic status (SES). This systematic review examines the association between the key SES indicators income, education, and occupation on breast cancer outcomes among the US breast cancer patients.MethodsAn electronic search was conducted using Medline®, Embase®, and Web of Science, from inception to December 2023. Observational studies examining the influence of SES indicators on breast cancer outcomes, including treatment receipt, adherence, and survival, were included. Data were summarized qualitatively due to heterogeneity in SES measures and outcome definitions.ResultsOf 2600 studies retrieved from the searches, 23 studies met the inclusion criteria (19 cohort, 4 cross-sectional). Women with lower SES were less likely to receive or experience delay in receiving the recommended treatment than women with higher SES. In addition, women with low household income (<$25,000) were more likely to report discontinuations in therapy as compared to women with an income of $50,000 or more. Education level influenced treatment adherence and timely care, with higher educational attainment linked to improved survival rates. Occupational status impacted treatment continuity, with low-wage jobs and inflexible work schedules contributing to delays and discontinuation of care.ConclusionSES significantly influences breast cancer care and survival, with lower SES associated with delayed treatment, poorer adherence, and worse outcomes. Healthcare interventions and policies focusing on equitable access to quality care tailored to all women, regardless of their socioeconomic background, may improve breast cancer outcomes for the patients with various demographic characteristics in the US.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251341520"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12064903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence OF HPV IN a Peruvian Healthcare Network: A Descriptive Cross-Sectional Study.","authors":"Jhajaira M Araujo, Maria Ramon-Cotrina, Rosa Quispe-Martinez, Mayra Rios-Rios, Maribel Quispe-Gonzaga, Carlos O Saldaña-Reyes, Paula Medina, Melanie Cornejo, Joseph A Pinto, Richard Dyer","doi":"10.1177/10732748251318386","DOIUrl":"10.1177/10732748251318386","url":null,"abstract":"<p><strong>Introduction: </strong>Human papillomavirus (HPV) infection is a common sexually transmitted infection often associated with cancer development. This study aimed to estimate the prevalence of HPV in women receiving care at the AUNA healthcare network in Peru.</p><p><strong>Methods: </strong>We conducted an observational, descriptive, cross-sectional, retrospective study. A de-identified database of HPV-positive women who underwent the BD Onclarity™ HPV Assay between December 2018 and December 2021 at Auna clinics was analyzed. The database contained information regarding age, city, and HPV type. High-risk HPV types were analyzed individually (16, 18, 31, 45, 51, 52) and pooled [P1 (33, 58), P2 (56,59,66), and P3 (35,39,68)]. The study was approved by an independent research ethics committee in Peru.</p><p><strong>Results: </strong>Of 68,714 women included in the study, the HPV prevalence was 14.21% (N = 9765, 95%CI:13.95%-14.47%). The highest prevalence was detected in Piura (16.85%, 95%CI:15.40%-18.38%), where HPV-51, HPV-52, HPV-P1, HPV-P2, and HPV-P3 were most common compared to other Peruvian cities included in the study. In Arequipa, the prevalence was the lowest (13.58%, 95%CI:12.38%-14.85%), but the percentage prevalence of HPV-16 was the highest compared to other cities. The prevalence of multiple HPV infections was 2.88% (N = 1981, 95%CI:2.76%-3.01%), with most of them co-presenting two types of HPV (N = 1522). The most frequent co-occurrences were P2 and P3, P2 and 52, and P2 and 16. Among HPV-positive women, the mean age was 41.31 years (±9.48) and 25.29% were in the 31-35 years group. HPV-P2 was the most frequent in all age groups except in the 65-72 years group, where HPV-P3 was the most common.</p><p><strong>Conclusion: </strong>HPV prevalence was shown to be highest in Piura, with the most prevalent types being HPV-16, HPV-52, and HPV-P2 (HPV-56, -59, -66). HPV infection was found to be more frequent among women in the 31-35 years age group.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251318386"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Outcomes of Osimertinib in EGFR - Mutant Non-Small Cell Lung Cancer With Brain Metastases: Results From a Retrospective Study at Vietnam National Cancer Hospital.","authors":"Thi Nhu Hoa Nguyen, Quang Le Van, Phuong Nguyen Thi Bich, Hau Tran Thi, Van Tai Nguyen, The Dao Minh, Lien Nguyen Duc, Duong Phan Thanh, Lam Ngo Le, Chu Nguyen Van, Hoang Nguyen Cong, Duc Nguyen Dinh, Hung Kien Do","doi":"10.1177/10732748251348429","DOIUrl":"10.1177/10732748251348429","url":null,"abstract":"<p><p>IntroductionThis study aimed to evaluate the therapeutic effect of osimertinib and further to compare the results of osimertinib plus brain radiation vs. osimertinib monotherapy in advanced EGFR-mutant non-small cell lung cancer (NSCLC) patients with brain metastases (BMs).MethodsA retrospective study was conducted involving 62 advanced EGFR-mutant NSCLC patients with BMs who were treated with first-line osimertinib at the Vietnam National Cancer Hospital between April 2019 and December 2023. Patients were categorised in two treatment groups: (1) osimertinib alone (33 patients) and (2) osimertinib combined with locoregional therapy, including stereotactic radiosurgery or whole-brain radiotherapy (29 patients). Endpoints included objective response rate (ORR), central nervous system response rate (CNS-ORR), progression-free survival (PFS), overall survival (OS).ResultsThe systemic ORR was 91.9% and the disease-control rate (DCR) was 96.8%. The CNS-ORR was 91.9% and the CNS-DCR was 100%. The median PFS and median OS achieved were 24.5 and 35.2 months, respectively. There was no significant difference in outcomes between patients in either treatment group with respect to CNS-ORR ( <i>P</i> = 1.0), mean best percentage change from baseline in CNS target lesion size (<i>P</i> = .376), median PFS (<i>P</i> = .656), intracranial progression-free survival (iPFS) (<i>P</i> = .706), or OS (<i>P</i> = .734). The occurrence of any-grade adverse events (AEs) did not differ significantly between the two treatment groups (<i>P</i> = .762). However, in the osimertinib plus brain radiation cohort, 3/29 (10.3%) patients experienced radiotherapy-related AEs (2 cases of brain necrosis, 1 case of leukoencephalopathy), which consisted of one case of grade 3 brain radiation necrosis.ConclusionOsimertinib shows favorable real-world outcomes in improving PFS, OS, and CNS-ORR in advanced EGFR-mutant NSCLC Vietnamese patients with BMs, with no clear additional benefit from combining with brain radiotherapy.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251348429"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12163268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144286913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}